Genome-wide CRISPR-Cas9 screening identifies CLK1 inhibition as a strategy to restore PARP inhibitor sensitivity via ERCC1 isoform switching
Protein & Cell · 2026
DOI: 10.1093/procel/pwaf091 ↗Kurz gefasst
Fachartikel in der Zeitschrift Protein & Cell, 2026. Verfasst von Chaohua Liu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Protein-Tyrosine Kinases, Endonucleases, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Anti-Cancer Association, Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
Epithelial ovarian cancer (EOC) is an aggressive malignancy with limited therapeutic options. Poly(ADP-ribose) polymerase inhibitors (PARPi) have shown remarkable efficacy, especially in BRCA-mutant patients, and are approved as maintenance therapy to prevent recurrence after initial response to chemotherapy. However, the development of PARPi resistance poses a major clinical challenge. This study utilized a whole-genome CRISPR-Cas9 genetic screening to identify genes associated with PARPi sensitivity upon knockout. Based on the screening and validated through further experiments, we confirmed that CLK1 knockdown is synthetically lethal with PARPi in ovarian cancer. The combination of the PARPi Olaparib and CLK1 inhibitor TG003 exhibited potent anti-proliferative effects both in vitro and in vivo. Mechanistically, CLK1 inhibition downregulated the functional ERCC1-202 isoform, resulting in enhanced DNA damage and apoptosis. Our findings reveal a novel mechanism underlying PARPi sensitivity and suggest that targeting CLK1 in combination with PARPi may represent a promising therapeutic strategy for PARPi-resistant ovarian cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
- Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
- Department of Gynecological Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310024, China.
Förderung
- National Natural Science Foundation of China
- Shanghai Anti-Cancer Association
- Science and Technology Commission of Shanghai Municipality
- Chinese Anti-Cancer Association-Hengrui PARP Inhibitor Cancer Research Fund
- Noncommunicable Chronic Diseases-National Science and Technology Major
- Social Development Project of Public Welfare Technology Research in Zhejiang Province
Zitieren
APA
Liu, C., Xu, F., Wu, Y., Li, J., Ni, M., Xia, S., Chen, L., Zhao, H., Yu, M., Zhou, Y., Zhang, M., Li, J., Wu, X., Huang, Y., Zhu, T., & Chen, X. (2026). Genome-wide CRISPR-Cas9 screening identifies CLK1 inhibition as a strategy to restore PARP inhibitor sensitivity via ERCC1 isoform switching. Protein & Cell. https://doi.org/10.1093/procel/pwaf091
Vancouver
Liu C, Xu F, Wu Y, Li J, Ni M, Xia S, et al. Genome-wide CRISPR-Cas9 screening identifies CLK1 inhibition as a strategy to restore PARP inhibitor sensitivity via ERCC1 isoform switching. Protein & Cell. 2026. doi:10.1093/procel/pwaf091
BibTeX
@article{Liu2026,
author = {Liu, Chaohua and Xu, Fei and Wu, Yutuan and Li, Jiana and Ni, Mengdong and Xia, Siyu and Chen, Lihua and Zhao, Haiyun and Yu, Min and Zhou, Yuqi and Zhang, Meiqin and Li, Jiajia and Wu, Xiaohua and Huang, Yan and Zhu, Tao and Chen, Xiaojun},
title = {Genome-wide CRISPR-Cas9 screening identifies CLK1 inhibition as a strategy to restore PARP inhibitor sensitivity via ERCC1 isoform switching},
journal = {Protein & Cell},
year = {2026},
doi = {10.1093/procel/pwaf091}
}
EUVIMED